• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的应用
Womens Health (Lond). 2018 Jan-Dec;14:1745505717750694. doi: 10.1177/1745505717750694.
2
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.聚（ADP - 核糖）聚合酶抑制在卵巢癌治疗中的研究进展
J Transl Med. 2016 Sep 15;14:267. doi: 10.1186/s12967-016-1027-1.
3
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.聚（ADP - 核糖）聚合酶抑制剂在高级别浆液性卵巢癌中的临床应用
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
4
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].[从聚（ADP - 核糖）的发现到PARP抑制剂在癌症治疗中的应用]
Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
5
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.妇科癌症中的新型靶向药物：合成致死、同源重组缺陷与PARP抑制剂
Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9.
6
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.美国食品和药物管理局批准的聚（ADP-核糖）聚合酶抑制剂维持治疗复发性卵巢癌：成本效益分析。
Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
7
Veliparib: a new therapeutic option in ovarian cancer?维利帕尼：卵巢癌的新治疗选择？
Future Oncol. 2019 Jun;15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10.
8
[Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].[聚（ADP - 核糖）聚合酶抑制剂——现状与未来发展]
Gan To Kagaku Ryoho. 2016 Feb;43(2):193-7.
9
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.聚（ADP - 核糖）聚合酶（PARP）抑制剂与卵巢癌
Taiwan J Obstet Gynecol. 2017 Oct;56(5):713-714. doi: 10.1016/j.tjog.2017.08.026.
10
Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.卵巢癌中新型聚ADP核糖聚合酶抑制剂联合策略
Curr Opin Obstet Gynecol. 2018 Feb;30(1):7-16. doi: 10.1097/GCO.0000000000000428.

引用本文的文献

1
Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis.蛋白质组学分析揭示了黄芪甲苷通过诱导细胞凋亡治疗非小细胞肺癌的分子机制。
BMC Complement Med Ther. 2023 Dec 15;23(1):461. doi: 10.1186/s12906-023-04305-0.
2
Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.遗传性癌症监测的当前和新前沿：液体活检的机会。
Am J Hum Genet. 2023 Oct 5;110(10):1616-1627. doi: 10.1016/j.ajhg.2023.08.014.
3
Pharmaceutical Management of Ovarian Cancer: Current Status.卵巢癌的药物治疗管理：现状。
Drugs. 2019 Jul;79(11):1231-1239. doi: 10.1007/s40265-019-01158-1.
4
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.在一项聚（ADP-核糖）聚合酶（PARP）抑制剂机会窗试验中的适应性反应表明，病灶间功能异质性有限，并显示出潜在的联合治疗方案。
Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947.
5
Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.靶向去 PAR 化选择性抑制 DNA 修复缺陷和 PARP 抑制剂耐药的恶性肿瘤。
Sci Adv. 2019 Apr 10;5(4):eaav4340. doi: 10.1126/sciadv.aav4340. eCollection 2019 Apr.

本文引用的文献

1
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.奥拉帕利片作为 BRCA1/2 突变的铂敏感复发性卵巢癌患者的维持治疗（SOLO2/ENGOT-Ov21）：一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.
2
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.循环肿瘤 DNA 中检测到的 BRCA1/2 种系突变在高级别浆液性卵巢癌患者中的逆转。
J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.
3
PARP inhibitors: Synthetic lethality in the clinic.聚（ADP-核糖）聚合酶抑制剂：临床中的合成致死性
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.
4
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.BRCA1/2 基因种系突变与遗传性乳腺癌-卵巢癌综合征（HBOC）的发生密切相关，具有 BRCA1/2 基因种系突变的个体终生患乳腺癌和卵巢癌的风险分别为 50%～85%和 15%～40%。 **注释**：以上是对英文文本的翻译，仅供参考。
J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.
5
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌（ARIEL2 研究第 1 部分）：一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
6
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
7
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
8
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.奥拉帕利单药治疗对携带胚系BRCA1/2突变、患有晚期卵巢癌且接受过三线或更多线既往治疗患者的疗效和安全性。
Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23.
9
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.奥拉帕利联合化疗治疗复发性铂类敏感卵巢癌：一项随机 2 期临床试验。
Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.
10
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.奥拉帕利单药治疗携带胚系 BRCA1/2 突变的晚期癌症患者。
J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的应用

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.

作者信息

Markman Maurie

机构信息

1 Cancer Treatment Centers of America, Philadelphia, PA, USA.

2 Drexel University College of Medicine, Philadelphia, PA, USA.

出版信息

Womens Health (Lond). 2018 Jan-Dec;14:1745505717750694. doi: 10.1177/1745505717750694.

DOI:10.1177/1745505717750694
PMID:29313444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5784554/
Abstract

There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and particularly (although not exclusively) in the setting of known mutations in the BRCA gene. This review will briefly highlight the biological rational for the use of poly (ADP-ribose) polymerase inhibitors in this malignancy, followed by summary of currently available clinical data supporting the delivery of agents approved by the US Food and Drug Administration for non-investigative use.

摘要

临床妇科肿瘤学界对聚（ADP - 核糖）聚合酶抑制剂在卵巢上皮癌治疗中发挥关键作用的潜力，尤其是（尽管不仅限于）在已知BRCA基因存在突变的情况下，有着浓厚的兴趣和热情。本综述将简要阐述在这种恶性肿瘤中使用聚（ADP - 核糖）聚合酶抑制剂的生物学原理，随后总结目前可用的临床数据，这些数据支持美国食品药品监督管理局批准的用于非研究用途药物的应用。